a clinical traial to assess pharmacokinetic/pharmacodynamic profiles and safety of ckd-843

Conditions: Alopecia

Summary: a clinical traial to assess pharmacokinetic/pharmacodynamic profiles and safety of ckd-843

a randomized, open-label, and parallel study to assess pharmacokinetic/pharmacodynamic profiles and safety of ckd-843 in male volunteers

Eligibility criteria:
inclusion criteria: * those who aged between 19 to 50 inclusion of man who concerned about androgenic alopecia. * those who has body weight ≥ 50kg. * those who has calculated body mass index(bmi) of 18.5 ≤ \~ \< 27.0 kg/m2 * body mass index, kg/m2= body weight(kg)/\[height(m)2\] * those who consent to proper contraception and do not donate sperm until 6 months after the last administration of investigational product. * those who understanding the detailed description of this clinical trial and voluntarily decide to participate. exclusion criteria: * those who have clinically significant disease or medical history of hepatopathy, renal dysfunction, neurological disorder, immunity disorder, respiratory disorder, genitourinary system disorder, hemato-oncology disorder, cardiovascular disorder or psychical disorder * those who have history of hypersensitivity to active pharmaceutical ingredient, 5α-reductase inhibitor, tocopherol. * those who have the screening(d-28\~d-2) test results written below * ast, alt \> 1.25 times higher than upper normal level * total bilirubin \> 1.5 times higher than upper normal level * egfr (estimated glomerular filtration rate, which is calculated by mdrd) \< 60 ml/min/1.73m2 * "positive" or "reactive" test result of hepatitis b \& c, hiv, rpr * under 5 min resting condition, systolic blood pressure \>150 mmhg or \ 100 mmhg or \<50 mmhg * those who have a drug abuse history within one year or positive reaction on urine drug screening test. * those who received following drugs, which may affect results of clinical trial and safety ethical-the-counter (etc) drugs and herbal medicines within 14 days before the first administration and over-the-counter (otc) drugs, health foods and vitamin preparations within 7 days before the first administration of the investigational product. * those who take barbiturate and related (causing induction or inhibition of metabolism) drug within 30 days before the first administration of investigational product. * those who exceeding smoke consumption criteria or can't stop smoking during hospitalization period. * criteria: smoke \> 10 cigarettes/day * those who exceeding an alcohol and caffeine consumption criteria or can't stop consuming alcohol and caffeine during hospitalization period. * criteria: caffeine \> 5 cups/day, alcohol \> 210 g/week * those who took grapefruit within 7 days before the first administration of investigational product. * those who received investigational product by participating in other clinical trial within 6 months before the first administration of investigational product. * those who donated whole blood within 60 days or apheresis within 30 days before the first administration of investigational product. * those who received transfusion within 30 days before the first administration of investigational product. * those who are deemed inappropriate to participate in clinical trial by investigators.